# A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

> **NCT05944224** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 63 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SPH4336
- **DRUG:** Cadonilimab

## Key facts

- **NCT ID:** NCT05944224
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-17
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05944224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05944224, "A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05944224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*